Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acromegaly - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H2 2017, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape. Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 4, 1, 6 and 3 respectively. Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders). - The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Acromegaly - Overview Acromegaly - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Acromegaly - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Acromegaly - Companies Involved in Therapeutics Development Aegis Therapeutics LLC Amryt Pharma plc Antisense Therapeutics Ltd Chiasma Inc Crinetics Pharmaceuticals Inc Daewoong Pharmaceutical Co Ltd Dauntless Pharmaceuticals Inc DexTech Medical AB Foresee Pharmaceuticals LLC Glide Pharmaceutical Technologies Ltd Ionis Pharmaceuticals Inc Ipsen SA Italfarmaco SpA Midatech Pharma Plc Novartis AG Peptron Inc Silence Therapeutics Plc Strongbridge Biopharma plc Sun Pharma Advanced Research Company Ltd Acromegaly - Drug Profiles Antisense Oligonucleotide to Inhibit Growth Hormone Receptor for Acromegaly - Drug Profile Product Description Mechanism Of Action R&D Progress AP-102 - Drug Profile Product Description Mechanism Of Action R&D Progress atesidorsen sodium - Drug Profile Product Description Mechanism Of Action R&D Progress BIM-23B065 - Drug Profile Product Description Mechanism Of Action R&D Progress CRN-00808 - Drug Profile Product Description Mechanism Of Action R&D Progress FP-002 - Drug Profile Product Description Mechanism Of Action R&D Progress IONIS-GHRLRx - Drug Profile Product Description Mechanism Of Action R&D Progress ITF-2984 - Drug Profile Product Description Mechanism Of Action R&D Progress lanreotide SR - Drug Profile Product Description Mechanism Of Action R&D Progress octreotide acetate - Drug Profile Product Description Mechanism Of Action R&D Progress octreotide acetate - Drug Profile Product Description Mechanism Of Action R&D Progress octreotide acetate - Drug Profile Product Description Mechanism Of Action R&D Progress octreotide acetate - Drug Profile Product Description Mechanism Of Action R&D Progress octreotide acetate long acting - Drug Profile Product Description Mechanism Of Action R&D Progress octreotide acetate SR - Drug Profile Product Description Mechanism Of Action R&D Progress octreotide SR - Drug Profile Product Description Mechanism Of Action R&D Progress octreotide SR - Drug Profile Product Description Mechanism Of Action R&D Progress Somadex - Drug Profile Product Description Mechanism Of Action R&D Progress SXN-101959 - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile Product Description Mechanism Of Action R&D Progress veldoreotide - Drug Profile Product Description Mechanism Of Action R&D Progress Acromegaly - Dormant Projects Acromegaly - Discontinued Products Acromegaly - Product Development Milestones Featured News & Press Releases Sep 04, 2017: Midatech Submits MTD201 CTA Filing For First-in Human Study in Carcinoid Cancer And Acromegaly Aug 10, 2017: Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly Jul 13, 2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808 May 04, 2017: Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery Mar 10, 2017: Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility Feb 16, 2017: Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery Feb 06, 2017: Amryt Pharma Announces positive pre-clinical study results for drug compound with potential to treat acromegaly, AP102 Dec 02, 2016: Amryt Pharma provides update on AP-102 Nov 07, 2016: FDA Orphan Drug Designation Received for Drug Compound with Potential to Treat Acromegaly Sep 22, 2016: Aegis Awarded Patent for Non-Invasive Nasal Octreotide Formulation Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study Jul 13, 2016: ATL1103 Patent Update Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa Jun 01, 2016: Antisense provides update on ATL1103 clinical trials Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Acromegaly, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Acromegaly - Pipeline by Aegis Therapeutics LLC, H2 2017 Acromegaly - Pipeline by Amryt Pharma plc, H2 2017 Acromegaly - Pipeline by Antisense Therapeutics Ltd, H2 2017 Acromegaly - Pipeline by Chiasma Inc, H2 2017 Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017 Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H2 2017 Acromegaly - Pipeline by DexTech Medical AB, H2 2017 Acromegaly - Pipeline by Foresee Pharmaceuticals LLC, H2 2017 Acromegaly - Pipeline by Glide Pharmaceutical Technologies Ltd, H2 2017 Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H2 2017 Acromegaly - Pipeline by Ipsen SA, H2 2017 Acromegaly - Pipeline by Italfarmaco SpA, H2 2017 Acromegaly - Pipeline by Midatech Pharma Plc, H2 2017 Acromegaly - Pipeline by Novartis AG, H2 2017 Acromegaly - Pipeline by Peptron Inc, H2 2017 Acromegaly - Pipeline by Silence Therapeutics Plc, H2 2017 Acromegaly - Pipeline by Strongbridge Biopharma plc, H2 2017 Acromegaly - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 Acromegaly - Dormant Projects, H2 2017 Acromegaly - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
